Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Merck has also decided to end the favezelimab clinical development program
Venus Remedies secures marketing authorization in Philippines
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Subscribe To Our Newsletter & Stay Updated
